Legal status in the United States

Peptide legal status: FDA, DEA and WADA, compound by compound

Read at FDA, DEA and WADAPublished by PepVault

Of the 93 compounds below, 21 have an FDA-approved product and 72 have none (14 of those are in company trials); none is a federally controlled substance, and WADA bans 24 of them in sport.

How many are approved

FDA-approved: 21; In clinical trials, not approved: 14; Not approved: 58FDA-approved21In clinical trials, not approved14Not approved58
93 compounds, by FDA status, read Nov 18, 2026.
A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Every compound, read Nov 18, 2026

FDA-approved

An FDA-approved drug holds this active ingredient (where Drugs@FDA lists every product as discontinued, the row says so).

CompoundFDA approvalCompoundingDEA scheduleSport (WADA)
SemaglutideApproved (Ozempic, 2017)Approved drug; not in shortageNot controlledNot named on the list
TirzepatideApproved (Mounjaro, 2022)Approved drug; not in shortageNot controlledNot named on the list
LiraglutideApproved (Victoza, 2010)Approved drug; FDA proposes no 503B listingNot controlledNot named on the list
TesamorelinApproved (Egrifta, 2010)A biologic; FDA: not eligible for 503A or 503BNot controlledBanned, named (S2.2.4)
HGHApproved (Humatrope, 1986)A biologic; FDA: not eligible for 503A or 503BNot controlled; own statute (21 U.S.C. 333(e))Banned, named (S2.2.3)
PT-141Approved (Vyleesi, 2019)Component of an approved drug (503A condition)Not controlledNot named on the list
SermorelinApproved 1990; discontinued (Drugs@FDA)Component of an approved drug (503A condition)Not controlledBanned, named (S2.2.4)
Semaglutide (oral)Approved (Rybelsus, 2019)Approved drug; not in shortageNot controlledNot named on the list
DulaglutideApproved (Trulicity, 2014)A biologic; FDA: not eligible for 503A or 503BNot controlledNot named on the list
OrforglipronApproved (Foundayo, 2026)Component of an approved drug (503A condition)Not controlledNot named on the list
Melanotan IApproved (Scenesse, 2019)Component of an approved drug (503A condition)Not controlledNot named on the list
ExenatideApproved (Byetta, 2005)Component of an approved drug (503A condition)Not controlledNot named on the list
SetmelanotideApproved (Imcivree, 2020)Component of an approved drug (503A condition)Not controlledNot named on the list
TeriparatideApproved (Forteo, 2002)Component of an approved drug (503A condition)Not controlledNot named on the list
AbaloparatideApproved (Tymlos, 2017)Component of an approved drug (503A condition)Not controlledNot named on the list
PramlintideApproved 2005; discontinued (Drugs@FDA)Component of an approved drug (503A condition)Not controlledNot named on the list
LinaclotideApproved (Linzess, 2012)Component of an approved drug (503A condition)Not controlledNot named on the list
SS-31Approved (Forzinity, 2025)Component of an approved drug (503A condition)Not controlledNot named on the list
OxytocinApproved (Syntocinon, 1980)Component of an approved drug (503A condition)Not controlledNot named on the list
HCGApproved (Chorionic Gonadotropin, 1973)A biologic; FDA: not eligible for 503A or 503BNot controlledBanned for males, named (S2.2.1)
ClomipheneApproved (Clomid, 1967)Component of an approved drug (503A condition)Not controlledBanned, named (S4.2)

In clinical trials, not approved

No FDA-approved product; a company trial is listed on ClinicalTrials.gov (each page links it).

CompoundFDA approvalCompoundingDEA scheduleSport (WADA)
RetatrutideNot approved; in phase 3 trialsBarred from compounding (FDA)Not controlledNot named; from 2027, S0 names peptides in general
MK-677Not approved; in a phase 3 trialOn FDA’s safety-risk list (category 2)Not controlledBanned, named (S2.2.4)
Thymosin Beta-4Not approved; in a phase 2 trialNot named on FDA’s listsNot controlledBanned, named (S2.3)
CagrilintideNot approved; in phase 3 trialsBarred from compounding (FDA)Not controlledNot named; from 2027, S0 names peptides in general
CagriSemaNot approved; in phase 3 trialsBarred from compounding (FDA)Not controlledNot named; from 2027, S0 names peptides in general
SurvodutideNot approved; in phase 3 trialsNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
PemvidutideNot approved; in a phase 3 trialNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
EloralintideNot approved; in phase 3 trialsNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
PetrelintideNot approved; in phase 3 trialsNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
AmycretinNot approved; in phase 3 trialsNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
VK2735Not approved; in phase 3 trialsNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
EnicepatideNot approved; in phase 3 trialsNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
EcnoglutideNot approved; in phase 3 trialsNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
LarazotideNot approved; in a phase 3 trialNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general

Not approved

No FDA-approved product.

CompoundFDA approvalCompoundingDEA scheduleSport (WADA)
BPC-157Not approvedNomination withdrawn; on no FDA listNot controlledBanned, named (S0)
TB-500Not approvedNomination withdrawn; on no FDA listNot controlledBanned, named (S2.3)
GHK-CuNot approvedUnder FDA evaluation, not for injection (503A category 1)Not controlledNot named; from 2027, S0 names peptides in general
Melanotan IINot approvedNomination withdrawn; on no FDA listNot controlledNot named; from 2027, S0 names peptides in general
CJC-1295 with DACNot approvedNomination withdrawn; on no FDA listNot controlledBanned, named (S2.2.4)
CJC-1295 no DACNot approvedNot checked yetNot controlledBanned by its class (S2.2.4)
IpamorelinNot approvedOn FDA’s safety-risk list for outsourcing facilities (503B category 2)Not controlledBanned, named (S2.2.4)
AOD-9604Not approvedNomination withdrawn; on no FDA listNot controlledBanned, named (S2.2.3)
SemaxNot approvedNomination withdrawn; on no FDA listNot controlledNot named; from 2027, S0 names peptides in general
NAD+Not approvedUnder FDA evaluation (503A category 1)Not controlledNot named on the list
MOTS-cNot approvedNomination withdrawn; on no FDA listNot controlledBanned, named (S4.4.1)
KPVNot approvedNomination withdrawn; on no FDA listNot controlledNot named; from 2027, S0 names peptides in general
EpitalonNot approvedNomination withdrawn; on no FDA listNot controlledNot named; from 2027, S0 names peptides in general
DSIPNot approvedNomination withdrawn; on no FDA listNot controlledNot named; from 2027, S0 names peptides in general
SelankNot approvedNomination withdrawn; on no FDA listNot controlledNot named; from 2027, S0 names peptides in general
Thymosin Alpha-1Not approvedNomination withdrawn; on no FDA listNot controlledNot named; from 2027, S0 names peptides in general
LL-37Not approvedNomination withdrawn; on no FDA listNot controlledNot named; from 2027, S0 names peptides in general
DihexaNot approvedNomination withdrawn; on no FDA listNot controlledNot named on the list
PEG-MGFNot approvedNomination withdrawn; on no FDA listNot controlledBanned by its class (S2.3)
IGF-1 LR3Not approvedNot named on FDA’s listsNot controlledBanned by its class (S2.3)
Kisspeptin-10Not approvedOn FDA’s safety-risk list (category 2)Not controlledBanned for males, by its class (S2.2.1)
GHRP-2Not approvedSafety-risk list for outsourcing facilities (503B category 2)Not controlledBanned, named (S2.2.4)
GHRP-6Not approvedSafety-risk list for outsourcing facilities (503B category 2)Not controlledBanned, named (S2.2.4)
HexarelinNot approvedNot named on FDA’s listsNot controlledBanned, named (S2.2.4)
VIPNot approvedUnder FDA evaluation (503A category 1)Not controlledNot named; from 2027, S0 names peptides in general
MazdutideNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
EfinopegdutideNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
ThymalinNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
ThymogenNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
VilonNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
CartalaxNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
PinealonNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
VesugenNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
LivagenNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
BronchogenNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
PancragenNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
CardiogenNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
ProstamaxNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
OvagenNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
CortagenNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
HumaninNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
FOXO4-DRINot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
SNAP-8Not approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
P21Not approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
CerebrolysinNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
N-Acetyl Semax AmidateNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
AdamaxNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
Ac-SDKPNot approvedNot named on FDA’s listsNot controlledNot named; from 2027, S0 names peptides in general
KlothoNot approvedNot named on FDA’s listsNot controlledNot named on the list
NMNNot approvedNot named on FDA’s listsNot controlledNot named on the list
5-Amino-1MQNot approvedNot named on FDA’s listsNot controlledNot named on the list
NSI-189Not approvedNot named on FDA’s listsNot controlledNot named on the list
Fragment 176-191Not approvedNot named on FDA’s listsNot controlledBanned, named (S2.2.3)
Follistatin-344Not approvedNot named on FDA’s listsNot controlledBanned, named (S4.3)
ARA-290Not approvedNominated without adequate support (503A category 3)Not controlledBanned by its class (S2.1.5)
EnclomipheneNot approvedUnder FDA evaluation (503A category 1)Not controlledBanned by its class (S4.2)
GlutathioneNo drug of its own; an ingredient of an eye-surgery rinseUnder FDA evaluation (503A category 1)Not controlledNot named on the list
SLU-PP-332Not approvedNot named on FDA’s listsNot controlledNot named in 2026; named from January 1, 2027 (S4.4.1)

What each column means

What this means and doesn’t

The table reports what the agencies’ own pages said in the United States when we read them on November 18, 2026; each compound’s page links every source. It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ.

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo